ANTONIO I VILLARREAL 302 , INFONAVIT LA HUASTECA,
KENNY 1 TIENDA DE CONVENIENCIA
H. J. DEPOSITO CON VENTA DE
FASEB Federation of American Societies for Experimental Biology
JAMA Journal of the American Medical Association
JACC Journal of the American College of Cardiology
REFERENCES
1. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. National Vital
Statistics Reports 2013;61(4):1-‐117.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349(9063):1436-‐1442. 3. McGill HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of Serum
Lipoproteins and Smoking on Atherosclerosis in Young Men and Women.
Arteriosclerosis, Thrombosis, and Vascular Biology 1997;17(1):95-‐106.
4. C DP. Hypertension and atherosclerosis. Journal of Human Hypertension 1996;10 Suppl 3:S89-‐92.
5. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:
Epidemiology, pathophysiology, and management. JAMA 2002;287(19):2570-‐ 2581.
6. Gonzalez ER, Kannewurf BS. Atherosclerosis: a unifying disorder with diverse manifestations. American Journal of Health-‐System Pharmacy 1998;55(19 Suppl 1):S4-‐7.
7. Welt FGP, Rogers C. Inflammation and restenosis in the stent era.
Arteriosclerosis, Thrombosis, and Vascular Biology 2002;22(11):1769-‐1776.
8. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nature Immunology 2005;6(12):1191-‐1197.
9. Miyahara T, Runge S, Chatterjee A, et al. D-‐series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J 2013;27(6):2220-‐2232.
10. Libby P. Inflammation in atherosclerosis. Nature 2002;420(6917):868-‐874. 11. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease.
New England Journal of Medicine 2005;352(16):1685-‐1695.
12. Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation 2002;105(9):1135-‐1143.
13. Stary HC, Chandler AB, Dinsmore RE, et al. A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis A Report From the Committee on Vascular Lesions of the Council on
Arteriosclerosis, American Heart Association. Circulation 1995;92(5):1355-‐ 1374.
14. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of Activated Mast Cells at the Site of Coronary Atheromatous Erosion or Rupture in Myocardial Infarction. Circulation 1995;92(5):1084-‐1088.
15. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis, Thrombosis, and Vascular Biology 1986;6(2):131-‐138. 16. Leitinger N. Oxidized phospholipids as triggers of inflammation in
atherosclerosis. Molecular Nutrition & Food Research 2005;49(11):1063-‐1071. 17. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P.
Macrophage colony-‐stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. The American Journal of Pathology 1992;140(2):301.
18. Getz GS. The involvement of lipoproteins in atherogenesis. Evolving concepts.
Annals of the New York Academy of Sciences 1990;598:17-‐28.
19. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science
1991;251(4995):788-‐791.
20. Johnson JL. Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis. Cardiovascular Research 2014.
21. Jagadeesha DK, Takapoo M, Banfi B, Bhalla RC, Miller FJ. Nox1 transactivation of epidermal growth factor receptor promotes N-‐cadherin shedding and smooth muscle cell migration. Cardiovascular Research 2012;93(3):406-‐413. 22. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and
atherosclerotic plaque stability. Expert Review of Cardiovascular Therapy 2007;5(2):265-‐282.
23. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. Journal of American College of Cardiology 1990;15(7):1667-‐ 1687.
24. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture.
Circulation 1994;90(2):775-‐778.
25. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovascular research 2003;59(4):812-‐823.
26. Bruschke AV, Kramer JR, Bal ET, Haque IU, Detrano RC, Goormastic M. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times.
American Heart Journal 1989;117(2):296-‐305.
27. Yokoya K, Takatsu H, Suzuki T, et al. Process of Progression of Coronary Artery Lesions From Mild or Moderate Stenosis to Moderate or Severe Stenosis A Study Based on Four Serial Coronary Arteriograms per Year.
Circulation 1999;100(9):903-‐909.
28. Flower RJ. The development of COX2 inhibitors. Nature Reviews. Drug
Discovery 2003;2(3):179-‐191.
29. Taylor PC, Feldmann M. Anti-‐TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nature Reviews. Rheumatology 2009;5(10):578-‐582. 30. Hagiwara M, Kurita-‐Ochiai T, Kobayashi R, Hashizume-‐Takizawa T, Yamazaki
K, Yamamoto M. Sublingual vaccine with GroEL attenuates atherosclerosis.
Journal of Dental Research 2014;93(4):382-‐387.
31. Mahoney EM, Wang K, Cohen DJ, et al. One-‐year costs in patients with a history of or at risk for atherothrombosis in the United States. Circulation 2008;1(1):38-‐45.
32. Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circulation 2010;3(6):642-‐651.
33. Muto A, Model L, Ziegler K, Eghbalieh SDD, Dardik A. Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies. Circulation Journal 2010;74(8):1501-‐1512. 34. Hoch JR, Stark VK, Hullett DA, Turnipseed WD. Vein graft intimal hyperplasia:
leukocytes and cytokine gene expression. Surgery 1994;116(2):463-‐470; discussion 470-‐471.
35. Tanaka H, Sukhova GK, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993;88(4 Pt 1):1788-‐1803.
36. Welt FG, Edelman ER, Simon DI, Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-‐injured arteries.
Arteriosclerosis, Thrombosis, and Vascular Biology 2000;20(12):2553-‐2558.
37. Luo Z, Asahara T, Tsurumi Y, Isner JM, Symes JF. Reduction of vein graft
intimal hyperplasia and preservation of endothelium-‐dependent relaxation by topical vascular endothelial growth factor. Journal of Vascular Surgery
1998;27(1):167-‐173.
38. Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia.
Immunology and Cell Biology 2006;84(2):115-‐124.
39. Turner NA, Hall KT, Ball SG, Porter KE. Selective gene silencing of either MMP-‐ 2 or MMP-‐9 inhibits invasion of human saphenous vein smooth muscle cells.
Atherosclerosis 2007;193(1):36-‐43.
40. Rocha-‐Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease.
Catheterization and Cardiovascular Interventions 2007;69(6):910-‐919.
41. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115(21):2745-‐2749.
42. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-‐segment self-‐expanding nitinol stents in the femoropopliteal arteries.
Journal of Endovascular Therapy 2005;12(1):6-‐12.
43. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Journal of Vascular Surgery 2006;43(4):742-‐751.e1. 44. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-‐Society Consensus for the
Management of Peripheral Arterial Disease (TASC II). Journal of Vascular
45. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular
inflammation and repair: implications for re-‐endothelialization, restenosis, and stent thrombosis. JACC 2011;4(10):1057-‐1066.
46. Gouëffic Y, Potter-‐Perigo S, Chan CK, et al. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis 2007;195(1):23-‐30.
47. Park J, Ha H, Ahn HJ, et al. Sirolimus inhibits platelet-‐derived growth factor-‐ induced collagen synthesis in rat vascular smooth muscle cells.
Transplantation Proceedings 2005;37(8):3459-‐3462.
48. Bhatia V, Bhatia R, Dhindsa M. Drug-‐eluting stents: new era and new concerns.
Postgraduate Medical Journal 2004;80(939):13-‐18.
49. Costa MA, Simon DI. Molecular basis of restenosis and drug-‐eluting stents.
Circulation 2005;111(17):2257-‐2273.
50. Garg P, Mauri L. The conundrum of late and very late stent thrombosis following drug-‐eluting stent implantation. Current Opinion in Cardiology 2007;22(6):565-‐571.
51. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-‐eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation
2008;118(11):1138-‐1145.
52. Tabas I, Glass CK. Anti-‐inflammatory therapy in chronic disease: challenges and opportunities. Science 2013;339(6116):166-‐172.
53. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel Functional Sets of Lipid-‐Derived Mediators with Antiinflammatory Actions Generated from Omega-‐3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing. The Journal of
Experimental Medicine 2000;192(8):1197-‐1204.
54. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-‐3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. The Journal of Experimental Medicine 2002;196(8):1025-‐1037.
55. Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. The Journal of
56. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circulation Research 2010;107(10):1170-‐1184.
57. Serhan CN. Resolution phase of inflammation: novel endogenous anti-‐
inflammatory and proresolving lipid mediators and pathways. Annual Review
of Immunology 2007;25:101-‐137.
58. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009;461(7268):1287-‐1291. 59. Hong S, Gronert K, Devchand PR, Moussignac R-‐L, Serhan CN. Novel
docosatrienes and 17S-‐resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-‐inflammation.
The Journal of Biological Chemistry 2003;278(17):14677-‐14687.
60. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-‐3 fatty acid-‐ derived mediators 17(R)-‐hydroxy docosahexaenoic acid, aspirin-‐triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. Journal of
Immunology 2011;187(4):1957-‐1969.
61. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-‐3-‐polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature Medicine 2007;13(7):868-‐873.
62. Hasturk H, Kantarci A, Ohira T, et al. RvE1 protects from local inflammation and osteoclast-‐ mediated bone destruction in periodontitis. FASEB J.
2006;20(2):401-‐403.
63. Flower RJ. Prostaglandins, bioassay and inflammation. British Journal of
Pharmacology 2006;147 Suppl 1:S182-‐192.
64. Malawista SE, de Boisfleury Chevance A, van Damme J, Serhan CN. Tonic inhibition of chemotaxis in human plasma. Proceedings of the National
Academy of Sciences of the United States of America. 2008;105(46):17949-‐
17954.
65. Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. The New England
Journal of Medicine 1985;312(19):1217-‐1224.
66. Calder PC, Yaqoob P, Harvey DJ, Watts A, Newsholme EA. Incorporation of fatty acids by concanavalin A-‐stimulated lymphocytes and the effect on fatty
acid composition and membrane fluidity. The Biochemical Journal 1994;300 ( Pt 2):509-‐518.
67. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN. Neutrophil-‐mediated changes in vascular permeability are inhibited by topical application of
aspirin-‐triggered 15-‐epi-‐lipoxin A4 and novel lipoxin B4 stable analogues. The
Journal of Clinical Investigation 1998;101(4):819-‐826.
68. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008;22(10):3595-‐3606.
69. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-‐derived macrophages. Journal of Immunology
2000;164(4):1663-‐1667.
70. Maddox JF, Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. The Journal of Experimental Medicine 1996;183(1):137-‐146. 71. Lucas M, Stuart LM, Savill J, Lacy-‐Hulbert A. Apoptotic cells and innate
immune stimuli combine to regulate macrophage cytokine secretion. Journal
of Immunology 2003;171(5):2610-‐2615.
72. Ward C, Dransfield I, Murray J, Farrow SN, Haslett C, Rossi AG. Prostaglandin D2 and its metabolites induce caspase-‐dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-‐activated receptor-‐gamma-‐independent mechanism. Journal of
Immunology 2002;168(12):6232-‐6243.
73. Calder PC. n-‐3 fatty acids, inflammation and immunity: new mechanisms to explain old actions. The Proceedings of the Nutrition Society 2013;72(3):326-‐ 336.
74. Bannenberg GL, Chiang N, Ariel A, et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. Journal of Immunology 2005;174(7):4345-‐4355.
75. Ho KJ, Spite M, Owens CD, et al. Aspirin-‐triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. The American Journal of Pathology 2010;177(4):2116-‐2123.
76. Dona M, Fredman G, Schwab JM, et al. Resolvin E1, an EPA-‐derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 2008;112(3):848-‐855.
77. Golpon HA, Fadok VA, Taraseviciene-‐Stewart L, et al. Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J. 2004;18(14):1716-‐1718.
78. Gardemann A, Meyer F, Braun-‐Dullaeus R. [What the surgeon needs to know about basic new concepts of inflammation and their therapeutic
consequences: sanitation of inflammation is not a passive but rather an active process regulated by lipid mediators]. Zentralblatt Fur Chirurgie
2013;138(3):322-‐330.
79. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution.
Chemical Reviews 2011;111(10):5922-‐5943.
80. Van Hees NJM, Giltay EJ, Geleijnse JM, Janssen N, van der Does W. DHA Serum Levels Were Significantly Higher in Celiac Disease Patients Compared to Healthy Controls and Were Unrelated to Depression. Hashimoto K, ed. PLoS
ONE 2014;9(5):e97778.
81. Rhee Y, Paik M-‐J, Kim K-‐R, et al. Plasma free fatty acid level patterns according to cardiovascular risk status in postmenopausal women. Clinica Chimica Acta 2008;392(1–2):11-‐16.
82. Conquer JA, Holub BJ. Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-‐esterified fatty acid in subjects of Asian Indian background. Journal of Lipid Research 1998;39(2):286-‐292.
83. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-‐resolving and inflammatory lipid mediators in human tissue. American Journal of Physiology 2014;307(1):C39-‐54. 84. Sun Y-‐P, Oh SF, Uddin J, et al. Resolvin D1 and its aspirin-‐triggered 17R
epimer. Stereochemical assignments, anti-‐inflammatory properties, and enzymatic inactivation. The Journal of Biological Chemistry
2007;282(13):9323-‐9334.
85. Rius B, López-‐Vicario C, González-‐Périz A, et al. Resolution of inflammation in obesity-‐induced liver disease. Inflammation 2012;3:257.
86. Dainese E, Sabatucci A, Angelucci CB, Barsacchi D, Chiarini M, Maccarrone M. Impact of embedded endocannabinoids and their oxygenation by
lipoxygenase on membrane properties. ACS Chemical Neuroscience 2012;3(5):386-‐392.
87. Aparoy P, Leela T, Reddy RN, Reddanna P. Computational analysis of R and S isoforms of 12-‐Lipoxygenases: Homology modeling and docking studies.
Journal of Molecular Graphics and Modelling 2009;27(6):744-‐750.
88. Walters JN, Bickford JS, Beachy DE, et al. cPLA(2)α gene activation by IL-‐1β is dependent on an upstream kinase pathway, enzymatic activation and
downstream 15-‐lipoxygenase activity: a positive feedback loop. Cellular
Signaling 2011;23(12):1944-‐1951.
89. Wuest SJA, Crucet M, Gemperle C, Loretz C, Hersberger M. Expression and regulation of 12/15-‐lipoxygenases in human primary macrophages.
Atherosclerosis 2012;225(1):121-‐127.
90. Leigh NJ, Nelson JW, Mellas RE, Aguirre A, Baker OJ. Expression of Resolvin D1 Biosynthetic Pathways in Salivary Epithelium. JOURNAL OF DENTAL
RESEARCH 2014;93(3):300-‐305.
91. Magnusson LU, Lundqvist A, Asp J, et al. High expression of arachidonate 15-‐ lipoxygenase and proinflammatory markers in human ischemic heart tissue.
Biochemical and Biophysical Research Communications 2012;424(2):327-‐330.
92. Rong S, Cao Q, Liu M, et al. Macrophage 12/15 lipoxygenase expression increases plasma and hepatic lipid levels and exacerbates atherosclerosis.
Journal of Lipid Research 2012;53(4):686-‐695.
93. Arai H, Suzuki T, Takama K, Terao J. Reactivity of mammalian 15-‐lipoxygenase with phospholipids in large unilamellar liposomes. Biochemical and
Biophysical Research Communications 1996;228(3):675-‐682.
94. Ikei KN, Yeung J, Apopa PL, et al. Investigations of human platelet-‐type 12-‐ lipoxygenase: role of lipoxygenase products in platelet activation. Journal of
Lipid Research 2012;53(12):2546-‐2559.
95. Limor R, Kaplan M, Sharon O, et al. Aldosterone up-‐regulates 12-‐ and 15-‐ lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. Journal of Cellular Biochemistry 2009;108(5):1203-‐1210.
96. Wölle J, Welch KA, Devall LJ, Cornicelli JA, Saxena U. Transient overexpression of human 15-‐lipoxygenase in aortic endothelial cells enhances tumor necrosis factor-‐induced vascular cell adhesion molecule-‐1 gene expression.
97. Zhang Y-‐Y, Walker JL, Huang A, et al. Expression of 5-‐lipoxygenase in pulmonary artery endothelial cells. The Biochemical Journal 2002;361(Pt 2):267-‐276.
98. Qiu H, Strååt K, Rahbar A, Wan M, Söderberg-‐Nauclér C, Haeggström JZ. Human CMV infection induces 5-‐lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. The Journal of Experimental
Medicine 2008;205(1):19-‐24.
99. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-‐Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochimica Et
Biophysica Acta 2014.
100. Lin H-‐C, Lin T-‐H, Wu M-‐Y, et al. 5-‐Lipoxygenase inhibitors attenuate TNF-‐α-‐ induced inflammation in human synovial fibroblasts. PLoS ONE
2014;9(9):e107890.
101. Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chemical Reviews 2011;111(10):5866-‐5898.
102. Hassan NA, El-‐Bassossy HM, Mahmoud MF, Fahmy A. Caffeic acid phenethyl ester, a 5-‐lipoxygenase enzyme inhibitor, alleviates diabetic atherosclerotic manifestations: effect on vascular reactivity and stiffness. Chemico-‐Biological
Interactions 2014;213:28-‐36.
103. Hatmi M, Samama M-‐M, Elalamy I. [Prevention of thrombosis and vascular inflammation: importance of combined cyclooxygenase and 5-‐lipoxygenase inhibitors]. Journal Des Maladies Vasculaires 2006;31(1):4-‐9.
104. Ye Y, Lin Y, Perez-‐Polo JR, et al. Phosphorylation of 5-‐lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-‐inflammatory 15-‐epi-‐lipoxin a4 production. Journal of Immunology 2008;181(5):3515-‐3523.
105. Werz O, Szellas D, Steinhilber D, Rådmark O. Arachidonic Acid Promotes Phosphorylation of 5-‐Lipoxygenase at Ser-‐271 by MAPK-‐activated Protein Kinase 2 (MK2). The Journal of Biological Chemistry 2002;277(17):14793-‐ 14800.
106. Harris MB, Blackstone MA, Sood SG, et al. Acute activation and
phosphorylation of endothelial nitric oxide synthase by HMG-‐CoA reductase inhibitors. American Journal of Physiology 2004;287(2):H560-‐566.
107. Fredman G, Ozcan L, Spolitu S, et al. Resolvin D1 limits 5-‐lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-‐activated kinase pathway. Proceedings of the National Academy of Sciences of the United
States of America. 2014.
108. Wu L, Miao S, Zou L-‐B, et al. Lipoxin A4 inhibits 5-‐lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury. Journal of Molecular Neuroscience
2012;48(1):185-‐200.
109. Luo M, Jones SM, Flamand N, Aronoff DM, Peters-‐Golden M, Brock TG. Phosphorylation by protein kinase a inhibits nuclear import of 5-‐
lipoxygenase. The Journal of Biological Chemistry 2005;280(49):40609-‐40616. 110. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Laniado Schwartzman
M. A role for the mouse 12/15-‐lipoxygenase pathway in promoting epithelial wound healing and host defense. The Journal of Biological Chemistry
2005;280(15):15267-‐15278.
111. Serhan CN, Dalli J, Karamnov S, et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 2012;26(4):1755-‐1765.
112. Wang GJ, Sui XX, Simosa HF, Jain MK, Altieri DC, Conte MS. Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein.
Arteriosclerosis, Thrombosis, and Vascular Biology 2005;25(10):2081-‐2087.
113. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-‐resolving mediators. Blood 2012;120(15):e60-‐72.
114. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-‐Lipoxygenase: regulation of expression and enzyme activity. Trends in Biochemical Sciences
2007;32(7):332-‐341.
115. Kale A, Naphade N, Sapkale S, et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-‐ medicated schizophrenia patients: Implications for altered one-‐carbon metabolism. Psychiatry Research 2010;175(1–2):47-‐53.
116. Silverman ES, Du J, De Sanctis GT, et al. Egr-‐1 and Sp1 Interact Functionally with the 5-‐Lipoxygenase Promoter and Its Naturally Occurring Mutants.
American Journal of Respiratory Cell and Molecular Biology 1998;19(2):316-‐
117. Lee SA, Kim HJ, Chang KC, et al. DHA and EPA Down-‐regulate COX-‐2
Expression through Suppression of NF-‐kappaB Activity in LPS-‐treated Human Umbilical Vein Endothelial Cells. The Korean Journal of Physiology &
Pharmacology 2009;13(4):301-‐307.
118. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nature
Immunology 2001;2(7):612-‐619.
119. Serhan CN. Pro-‐resolving lipid mediators are leads for resolution physiology.
CURRICULUM VITAE